Many drugs commonly used in CF patients act as inhibitors or inducers of both CYP3A4 and CYP3A5 isoforms (for example, rifampicin, azole antifungals or macrolides antibiotics) leading to DDIs that could potentially alter “caftor” plasma concentrations [8]. This evidence concerns the gene CYP3A5 and cystic fibrosis.